Indications and efficacy of continuous subcutaneous insulin infusion (CSII) therapy in Type 1 diabetes mellitus: A clinical audit in a specialist service

Diabetic Medicine

Volumn 22, Issue 7, 2005, Pages 842-849

  Rodrigues, I A S ^a   Reid, H A ^b   Ismail, K ^c   Amiel, Stephanie A ^a,b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b KING S COLLEGE HOSPITAL   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Continuous subcutaneous insulin infusion; Contraindications; Diabetic ketoacidosis; Hypoglycaemia; Indications

Indexed keywords

HEMOGLOBIN A1C; INSULIN; INSULIN ASPART; INSULIN LISPRO;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; DIABETIC KETOACIDOSIS; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG INDICATION; FEMALE; HUMAN; HYPOGLYCEMIA; INFUSION PUMP; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN INFUSION; MALE; PRACTICE GUIDELINE; QUALITY OF LIFE; QUESTIONNAIRE; TREATMENT CONTRAINDICATION;

ADMINISTRATION, CUTANEOUS; ADOLESCENT; ADULT; CHILD; DIABETES MELLITUS, TYPE 1; DIABETIC ANGIOPATHIES; DIABETIC KETOACIDOSIS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN INFUSION SYSTEMS; MALE; MIDDLE AGED; PATIENT CARE TEAM; QUALITY OF LIFE; RECURRENCE; RISK FACTORS; TREATMENT OUTCOME;

EID: 21744436433     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2005.01539.x     Document Type: Article

References (26)

1. Lauritzen T, Pramming S, Deckert T, Binder C. Pharmacokinetics of continuous subcutaneous insulin infusion. Diabetologia 1983; 24: 326-329.
2. Hirsch IB. Intensive treatment of type 1 diabetes. In: Skyler JS, ed. Medical Clinics of North America, Prevention and Treatment of Diabetes and its Complications. Philadelphia: W.B. Saunders, 1998: 689-720.
3. National Institute for Clinical Excellence. Guidance on the Use of Continuous Subcutaneous Insulin Infusion for Diabetes. Technology Appraisal Guidance no. 57. Revised by the National Institute of Clinical Excellence (Nol94), London, 2003: 3.
4. Graff MR, Rubin RR, Walker EA. How diabetes specialists treat their own diabetes: findings from a study of the AADE and ADA membership. Diabetes Educ 2000; 26: 450-459.
5. Bode BW, Steed RD, Davidson PC. Reduction in severe hypoglycaemia with long term subcutaneous insulin infusion in type 1 diabetes. Diabetes Care 1996; 19: 324-327.
6. Hirsch IB, Farkas-Hirsch R, Cryer PE. Continuous subcutaneous insulin infusion for the treatment of diabetic patients with hypoglycaemia unawareness. Diabetes Nutr Metab 1991; 4: 41-43.
7. Farkas-Hirsch R, Hirsch IB. Continuous subcutaneous insulin infusion: a review of the past and its implementation for the future. Diabetes Spectrum 1994; 7: 80-84.
8. Bending JJ, Pickup JC, Collins ACG, Keen H. Rarity of a marked 'dawn phenomenon' in diabetic subjects treated by continuous subcutaneous insulin infusion. Diabetes Care 1985; 8: 28-33.
9. Coustan DR, Reece EA, Sherwin RS, Rudolf MC, Bates SE, Sockin SM et al. A randomized clinical trial of insulin pump vs intensive conventional therapy in diabetic pregnancies. J Am Med Assoc 1986; 255: 631-636.
10. Weissberg-Benchell J, Antisdel-Lomaglio J, Seshadri R. Insulin pump therapy: a meta-analysis. Diabetes Care 2003; 26: 1079-1087.
11. Bending JJ, Pickup JC, Keen H. Frequency of diabetic ketoacidosis and hypoglycemic coma during treatment with continuous subcutaneous insulin infusion. Audit of medical care. Am J Med 1985; 79: 685-691.
12. Wang PH, Lau J, Chalmers TC. Meta-analysis of effects of intensive blood-glucose control on late complications of type 1 diabetes. Lancet 1993; 341: 1306-1309.
13. Tamborlane WV, Ahern J. Implications and results of the diabetes control and complications trial. Pediatr Clin North Am 1997; 44: 285-300.
14. Steindel BS, Thomas RR, Costin G, Carlson M, Kaufman FR. Continuous subcutaneous insulin infusion (CSII) in children and adolescents with chronic poorly controlled type 1 diabetes mellitus. Diabetes Res Clin Pract 1995; 27: 199-204.
15. Scuffham P, Carr L. The cost-effectiveness of continuous subcutaneous insulin infusion compared with multiple daily injections for the management of diabetes. Diabet Med 2003; 20: 586-593.
16. Hunger-Dathe W, Braun A, Muller UA, Schiel R, Femerling M, Risse A. Insulin pump therapy in patients with Type 1 diabetes mellitus: results of the Nationwide Quality Circle in Germany (ASD) 1999-2000. Exp Clin Endocrinol Diabetes 2003; 111: 428-434.
17. Sanfield JA, Hegstad M, Hanna RS. Protocol for outpatient screening and initiation of continuous subcutaneous insulin infusion therapy: impact on cost and quality. Diabetes Educ 2002; 28: 599-607.
18. The DCCT Research Group. Reliability and validity of a Diabetes Quality of Life measure for the Diabetes Control and Complications Trial (DCCT). Diabetes Care 1998; 11: 725-732.
19. Hays RD, Sherbourne CD, Mazel RM. The RAND 36-item health survey 1.0. Health Econ 1993; 2: 217-227.
20. Cox DJ, Irvine A, Gonder-Fredrick L, Nowacek G, Butterfield J. Fear of hypoglycaemia: quantification, validation, and utilization. Diabetes Care 1987; 10: 617-621.
21. Bruttomesso D, Pianta A, Crazzolara D, Scaldaferri E, Lora L, Guarneri G et al. Continuous subcutaneous insulin infusion (CSII) in the Vento region: efficacy, acceptability and quality of life. Diabet Med 2002; 19: 628-634.
22. Linkeschova R, Raoul M, Bott U, Berger M, Spraul M. Less severe hypoglycaemia, better metabolic control, and improved quality of life in Type 1 diabetes mellitus with continuous subcutaneous insulin infusion (CSII) therapy; an observational study of 100 consecutive patients followed for a mean of 2 years. Diabet Med 2002; 19: 746-751.
23. Chantelau E, Schiffers T, Schultze J, Hansen B. Effect of patient-selected intensive insulin therapy on quality of life. Patient Educ Couns 1996; 30: 167-173.
24. Jornsay DL, Duckles AE, Hankinson JP. Psychological considerations for patient selection and adjustment to insulin pump therapy. Diabetes Educ 1988; 14: 291-296.
25. Frier BM, Deary IJ. Hypoglycaemia was validated. Br Med J 1995; 310: 1407a.
26. American Diabetes Association. Continuous subcutaneous insulin infusion (Position Statement). Diabetes Care 2003; 26 (Suppl. 1): S125.